Fintel reports that on December 17, 2025, BTIG initiated coverage of Samsara (NYSE:IOT) with a Buy recommendation. Analyst ...

Wondering if Samsara at around $41 a share is a hidden opportunity or just a hype story waiting to cool off? You are not alone in trying to figure out what this stock is really worth. The share price ...

Detailed price information for Samsara Inc Cl A (IOT-N) from The Globe and Mail including charting and trades.

Detailed price information for Samsara Inc Cl A (IOT-N) from The Globe and Mail including charting and trades.

The consensus price target hints at a 25.7% upside potential for Samsara Inc. (IOT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings ...

Samsara delivered a quarter that exceeded Wall Street’s expectations, with revenue growth fueled by continued expansion among ...

BTIG initiated coverage of Samsara (IOT) with a Buy rating and $55 price target Samsara has remained one of the fastest-growing software companies ...

Link Cell Therapies ("Link"), an oncology cell therapy company, today announced its official launch from stealth with a $60 million Series A financing that was led by Johnson & Johnson, through its ...

Physical AI can map the future of commercial driving to reduce costs, protect frontline workers with proactive safety, and ...

The private placement includes participation from both new and existing investors, including ADAR1 Capital Management, Coastlands Capital, Invus, RTW Investments, Samsara BioCapital, Woodline Partners ...

Cell therapy company Link Cell Therapies is launching with $60 million and a mission to develop potent CAR-T therapies that ...

Blizzard gave "Diablo" franchise fans what they've all been waiting years for Thursday during The 2025 Game Awards: the addition of the Paladin class ...